Who are Masked Ikervis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, CYCLOSPORINE VS INFLIXIMAB, Sandimmune® Injection, Cyclosporine 0.09% Ophthalmic Solution, Tacrolimus, Reddy Laboratory.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/masked-ikervis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Masked Ikervis — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Masked Ikervis (Masked Ikervis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor (ophthalmic). Area: Ophthalmology.

phase 3 Calcineurin inhibitor (ophthalmic) Calcineurin Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Masked Ikervis (Masked Ikervis) — Santen SAS. Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Masked Ikervis TARGET	Masked Ikervis	Santen SAS	phase 3	Calcineurin inhibitor (ophthalmic)	Calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)
Sandimmune® Injection	Sandimmune® Injection	NeuroVive Pharmaceutical AB	marketed	Calcineurin inhibitor	Calcineurin (via cyclophilin binding)
Cyclosporine 0.09% Ophthalmic Solution	Cyclosporine 0.09% Ophthalmic Solution	Center for Ophthalmic and Vision Research, LLC	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
Tacrolimus, Reddy Laboratory	Tacrolimus, Reddy Laboratory	University of Cincinnati	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (Calcineurin inhibitor (ophthalmic) class)

Santen SAS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Masked Ikervis — Competitive Intelligence Brief. https://druglandscape.com/ci/masked-ikervis. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing